Ticker

Mangoceuticals (NASDAQ: MGRX - Get Free Report) and Lipocine (NASDAQ: LPCN - Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, earnings, valuation and risk. Valuation and Earnings This table compares Mangoceuticals and Lipocine"s

Lipocine Inc. (NASDAQ: LPCN - Get Free Report) Director John Higuchi acquired 40,000 shares of the company's stock in a transaction that occurred on Tuesday, April 7th. The shares were bought at an average price of $2.03 per share, with a total value of $81,200.00. Following the transaction, the director owned 203,797 shares in the company,

Lipocine Inc. (NASDAQ: LPCN - Get Free Report) CEO Mahesh Patel bought 25,000 shares of the company's stock in a transaction on Monday, April 6th. The stock was bought at an average cost of $2.03 per share, for a total transaction of $50,750.00. Following the completion of the transaction, the chief executive officer directly owned 160,679

On Thursday, the company said LPCN 1154 did not meet its primary endpoint in a Phase 3 trial for postpartum depression (PPD).

SAN DIEGO, April 06, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Lipocine Inc. (NASDAQ: LPCN). The investigation focuses on Lipocine's executive officers and whether investor losses may be recovered under federal securities laws.